HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eccles, T. G. Articles by Francis, G. L. Search for Related Content PubMed PubMed Citation Articles by Eccles, T. G. Articles by Francis, G. L.

Erythropoietin and the Erythropoietin Receptor Are Expressed by Papillary Thyroid Carcinoma fromChildren and Adolescents.

Expression of Erythropoietin Receptor Might Be a Favorable Prognostic Indicator

Address correspondence to Gary L. Francis MD PhD, Department of Pediatrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA; tel 301 295 9716; fax 301 295 3898; email: gfrancis{at}usuhs.mil. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or to reflect the opinions of the Uniformed Services University of the Health Sciences, Walter Reed Army Medical Center, the Department of the Army, or the Department of Defense.

Erythropoietin (EPO) and the EPO receptor (EPO-R) have been implicated in solid tumors of the brain, breast, kidney and female genital tract. Based on their expression by a variety of tumors, we hypothesized that EPO and/or EPO-R might be expressed by thyroid cancers. To test this, we determined EPO and EPO-R expression by immunohistochemistry in 17 papillary thyroid carcinomas (PTC) from children and adolescents. Only a minority of PTC (4/17, 24%) expressed EPO, and there were no significant differences between the PTC that did or did not express EPO. In contrast, EPO-R was detected in the majority of PTC (11/17, 65%). The average tumor size (1.5 ± 0.8 cm), MACIS score (3.6 ± 0.2) and risk of recurrence (0/11) for the EPO-R(+) PTC were significantly less than those for PTC that failed to express EPO-R (average tumor size = 3.6 ± 2.4 cm, p = 0.021; average MACIS score = 4.3 ± 0.7, p = 0.004; recurrence = 3/6, p = 0.029). We conclude that the majority of PTC from children and adolescents express EPO-R, a finding associated with favorable prognostic indicators and a lower risk of recurrence.

Keywords: thyroid, cancer, erythropoietin, erythropoietin receptor

This article has been cited by other articles:

				W. M. Brown, P. Maxwell, A. N.J. Graham, A. Yakkundi, E. A. Dunlop, Z. Shi, P. G. Johnston, and T. R.J. Lappin Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity Stem Cells, March 1, 2007; 25(3): 718 - 722. [Abstract] [Full Text] [PDF]

				S. Elliott, L. Busse, M. B. Bass, H. Lu, I. Sarosi, A. M. Sinclair, C. Spahr, M. Um, G. Van, and C. G. Begley Anti-Epo receptor antibodies do not predict Epo receptor expression Blood, March 1, 2006; 107(5): 1892 - 1895. [Abstract] [Full Text] [PDF]

				M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]